Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: Effect of prior monovalent inactivated vaccine

Journal of Infectious Diseases

Volumn 209, Issue 11, 2014, Pages 1705-1714

  Gaglani, Manjusha ^a   Spencer, Sarah ^c   Ball, Sarah ^d   Song, Juhee ^b   Naleway, Allison ^e   Henkle, Emily ^e   Bozeman, Sam ^d   Reynolds, Sue ^c   Sessions, Wendy ^c   Hancock, Kathy ^c   Thompson, Mark ^c  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d ABT ASSOCIATES   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

2009 influenza pandemic H1N1; healthcare workers; hemagglutination inhibition antibody; influenza vaccine; influenza vaccine immunogenicity or response

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; MONOVALENT INACTIVATED VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; INFLUENZA A (H1N1); MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEASONAL INFLUENZA; TREATMENT DURATION; YOUNG ADULT;

2009 INFLUENZA PANDEMIC H1N1; HEALTHCARE WORKERS; HEMAGGLUTINATION INHIBITION ANTIBODY; INFLUENZA VACCINE; INFLUENZA VACCINE IMMUNOGENICITY OR RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; COHORT STUDIES; FEMALE; HEALTH PERSONNEL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84900534803     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit825     Document Type: Article

References (52)

1. Kuster SP, Shah PS, Coleman BL, et al. Incidence of influenza in healthy adults and healthcare workers: a systematic review and metaanalysis. PLoS One 2011; 6:e26239.
2. Pearson ML, Bridges CB, Harper SA; Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP). Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-2): 1-16.
3. Erratum in: MMWR Recomm Rep 2006; 55: 252.
4. Centers for Disease Control and Prevention (CDC). Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel-United States, August 2009- January 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 357-62.
5. Erratum in: MMWR Morb Mortal Wkly Rep 2010; 59: 397.
6. Ng AN, Lai CK. Effectiveness of seasonal influenza vaccination in healthcare workers: a systematic review. J Hosp Infect 2011; 79: 279-86.
7. Michiels B, Philips H, Coenen S, et al. The effect of giving influenza vaccination to general practitioners: a controlled trial [NCT00221676]. BMC Med 2006; 4: 17.
8. Michiels B, Philips H, Coenen S, Denekens J, Van Royen P. Serum antibodies against circulating influenza strains among vaccinated and unvaccinated general practitioners during two consecutive years (2002-2003). Vaccine 2006; 24: 3145-52.
9. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281: 908-13.
10. Saxén H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18: 779-83.
11. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979; 1: 33-5.
12. Feery BJ, Evered MG, Morrison EI. Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976. J Infect Dis 1979; 139: 237-41.
13. Brandriss MW, Betts RF, Mathur U, Douglas RG Jr. Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines. Am Rev Respir Dis 1981; 124: 681-4.
14. Powers RD, Hayden FG, Samuelson J, Gwaltney JM Jr. Immune response of adults to sequential influenza vaccination. J Med Virol 1984; 14: 169-75.
15. Pyhälä R, Kumpulainen V, Alanko S, Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine 1994; 12: 947-52.
16. Gross PA, Sperber SJ, Donabedian A, et al. Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Vaccine 1999; 17: 2284-9.
17. Erratum in: Vaccine 1999; 18: 955.
18. Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 2007; 79: 320-5.
19. Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine 2012; 30: 4240-8.
20. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, et al. Metaanalysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One 2011; 6:e24384.
21. Talaat KR, Greenberg ME, Lai MH, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 2010; 202: 1327-37.
22. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375: 41-8.
23. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361: 2405-13.
24. Thompson MG, Gaglani MJ, Naleway A, et al. The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine 2012; 30: 3557-65.
25. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. J Health Soc Behav 1997; 38: 21-37.
26. Prus SG. Comparing social determinants of self-rated health across the United States and Canada. Soc Sci Med 2011; 73: 50-9.
27. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59: 1-62.
28. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59: 901-8.
29. Centers for Disease Control and Prevention (CDC). Update: influenza activity- United States, 2010-2011 season, and composition of the 2011-12 influenza vaccine.MMWRMorbMortWkly Rep 2011; 60: 705-12.
30. Pierre Payment K, Trudel M. Methods and techniques in virology. New York: Marcel Dekker, Inc, 1993.
31. World Health Organization Global Influenza Surveillance Network. Serological diagnosis of influenza by haemagglutination inhibition testing. In: Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva, Switzerland: WHO, 2011: 59-62.
32. Beyer WE, Palache AM, Lüchters G, Nauta J, Osterhaus AD. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 2004; 103: 125-32.
33. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767-77.
34. Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) 1977; 79: 321-32.
35. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol 2003; 115: 63-73.
36. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690-1.
37. Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009; 37: 216-21.
38. Keitel WA, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1988; 127: 353-64.
39. Beyer WE, Palache AM, Sprenger MJ, et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1996; 14: 1331-9.
40. Künzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14: 1108-10.
41. Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 2011; 29: 5785-92.
42. Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 1999; 159: 182-8.
43. Sasaki S, He XS, Holmes TH, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008; 3:e2975.
44. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 1999; 96: 14001-6.
45. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997; 15: 1114-22.
46. Wagar LE, Rosella L, Crowcroft N, et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS One. 2011; 6: e28063.
47. Kumar S, Fan J, Melzer-Lange M, et al. H1N1 hemagglutinin-inhibition seroprevalence in emergency department health care workers after the first wave of the 2009 influenza pandemic. Pediatr Emerg Care 2011; 27: 804-7.
48. Reed C, Katz JM, Hancock K, Balish A, Fry AM; H1N1 Serosurvey Working Group. Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic. PLoS One 2012; 7:e48187.
49. Zhou Y, Ng DM, Seto WH, et al. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine. PLoS One 2011; 6:e27169.
50. Igari H, Segawa S, Watanabe A, et al. Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health-care workers of a university hospital in Japan. Microbiol Immunol 2010; 54: 618-24.
51. Huijskens E, Rossen J, Mulder P, et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011; 18: 1401-5.
52. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61: 613-8.